U.S. Markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
176.89+4.64 (+2.69%)
At close: 4:00PM EDT
175.85 -1.04 (-0.59%)
After hours: 07:20PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close172.25
Open171.08
Bid176.63 x 800
Ask175.85 x 800
Day's Range170.01 - 177.53
52 Week Range119.29 - 178.41
Volume1,522,882
Avg. Volume516,287
Market Cap20.793B
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-7.55
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est174.78
  • Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
    Business Wire

    Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from a Phase 3b open-label study conducted to evaluate the safety, efficacy and pharmacokinetics (PK) of patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy progression after receiving an orthotopic liver transplant (OLT). In patients treated with patisiran, the median reduction in serum TTR levels compared to baseline was 91 percent, measured as an aver

  • 2 Biotech Stocks ARK Invest Bought in June
    Motley Fool

    2 Biotech Stocks ARK Invest Bought in June

    Over the past few years, Cathie Wood's ARK Invest group of exchange-traded funds have delivered impressive gains. ARK Invest's most successful fund over the past year, the ARK Genomic Revolution ETF (NYSEMKT: ARKG) has the best performer of the bunch with an incredible 80% gain over the past 12 months. On Jun. 3, 2021, the ARK Genomic Revolution ETF bought shares of these two clinical-stage biotechs.

  • Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy
    Business Wire

    Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of cardiomyopathy in patients with transthyretin-mediated (ATTR) amyloidosis. Enrollment was completed with over 300 ATTR amyloidosis patients across 90 sites in more than 20 countries. ATTR amyloidosis is a rare, progressively debilitating, and fatal disease that is caused by misfolded transthyretin (TTR) proteins that accumulate as amyloid deposits in multiple tissues, including the nerves, heart and gastrointestinal (GI) tract and encompasses hereditary ATTR (hATTR) amyloidosis and wild-type ATTR (wtATTR) amyloidosis. hATTR amyloidosis is estimated to impact approximately 50,000 people worldwide and is a multisystem disease that can include sensory and motor, autonomic, and cardiac symptoms. wtATTR amyloidosis is estimated to impact between 200,000 and 300,000 people worldwide and primarily manifests as cardiomyopathy, which can lead to heart failure and mortality. APOLLO-B is the industry’s furthest progressed randomized, double-blind, placebo-controlled study of a TTR silencer investigational medicine for the treatment of cardiomyopathy in hATTR and wtATTR amyloidosis patients.